恩度与化疗联合治疗晚期消化道肿瘤的临床疗效.pdf

网络出版时间：2015-01-1608:54网络出版地址：CHINESECOMMUNITYDOCTORS论著·临床论坛恩度与化疗联合治疗晚期消化道肿瘤的临床疗效沙建彤672400云南省大理州巍山县人民医院doi:10.3969/j.issn.1007-614x.2015.2.10摘要目的：探讨晚期消化道肿瘤采取恩度结合化疗的临床应用价值。方法：2008年3月-2013年4月收治晚期消化道肿瘤患者76例，随机分为观察组和对照组，对照组采取化疗，观察组采取恩度联合化疗，对两组药物治疗效果给予分析研究。结果：观察组临床疾病控制率(76.31%)明显要比对照组(63.15%)高(P＜0.05)；观察组不良反应包括骨髓抑制3例、胃肠道反应4例、心电图T波改变1例、早搏1例、血压升高1例；对照组不良反应包括骨髓抑制4例、胃肠道反应6例、心电图T波改变2例、早搏1例、血压升高2例。差异无统计学意义(P＞0.05)。结论：晚期消化道肿瘤采取恩度联合化疗，可以使客观治疗效果明显提高，具有临床推广价值。关键词临床疗效；晚期消化道肿瘤；化疗；恩度ClinicalefficacyofendostarcombinedwithchemotherapyintreatmentofadvancedgastrointestinaltumorShaJiantongThePeople'sHospitalofWeishanCounty,DaliState,YunnanProvince672400AbstractObjective:Toinvestigatethevalueofclinicalapplicationofendostarcombinedwithchemotherapyintreatmentofadvancedgastrointestinaltumor.Methods:76patientswithadvancedgastrointestinaltumorswereselectedfromMarch2008toApril2013.Theywererandomlydividedintotheobservationgroupandthecontrolgroup.Thecontrolgroupweregivenchemotherapy.Theobservationgroupweregivenendostarcombinedwithchemotherapy.Weanalyzedandstudiedonthetherapeuticeffectoftwogroups.Results:Theclinicaldiseasecontrolrateoftheobservationgroup(76.31%)washigherthanthecontrolgroup(63.15%)(P＜0.05).Theobservationgrouptoxicitiesincludedmyelosuppressionin3cases,4casesofgastrointestinalreaction,TwaveofECGchangesin1case,1caseofprematurebeat,elevatedbloodpressurein1case;thecontrolgrouptoxicityreactionincluding4caseswithbonemarrowsuppression,gastrointestinalreactionsin6cases,TwaveofECGchangesin2cases,1caseofprematurebeat,elevatedbloodpressurein2cases;thedifferenceswasnotstatisticallysignificant(P＞0.05).Conclusion:Endostarcombinedwithchemotherapyinthetreatmentofadvanceddigestivetractcancercanmaketheobjectiveeffectobviously,andithasclinicalvalue.KeywordsClinicalcurativeeffect;Advanceddigestivetractcancer;Chemotherapy;Endostar恶性消化道肿瘤在临床当中非常常例；年龄34～70岁，平均(54.1±3.8)希罗达、伊立替康350mg/m2+氟尿嘧见，包括肠癌、食道癌、阑尾癌以及胰岁；疾病类型包括食道癌22例啶、FOLFOX6、FOLFOX4。⑥阑尾癌：腺癌等，给患者生命安全带来巨大的威(57.89%)、胰腺癌3例(7.89%)、胆囊癌5奥沙利铂+希罗达。21d为1个疗程，连胁。目前